In this chapter, Dr. Jones talks about the graduate research that brought him to MD Anderson. He sketches the story of how he left the University of California, San Francisco to join MD Anderson to develop a research lab in endocrinology. He describes the research he conducted at on combined therapies for gynecologic diseases. In particular, his research had to do with the long-term impact of DES (diethylstilbestrol -synthetic estrogen) in promoting cancer, the work for which he is best known. He explains how his interest in medicine and oncology developed. He lists the individuals he worked with and describes the state of the field at the time. Next Dr. Jones explains that at MD Anderson he was hired to develop a pioneering model o...
Dr. Gehan recollects Dr. R. Lee Clark’s approach to funding, recruitment, and management and the att...
Dr. Alexanian explains how he came to MD Anderson in 1964, then then talks about the evolution of hi...
Dr. Arlinghaus explains his reasons for focusing on leukemia research and the process of coming to M...
In this chapter, Dr. Jones talks about the graduate research that brought him to MD Anderson. He sk...
Dr. Jones talks his role in the Department of Gynecologic Oncology: to bring reproductive endocrinol...
To begin this segment, Dr. Rodriguez sketches her research while a Fellow at the University of Arizo...
In this segment, Dr. Kripke covers her arrival at MD Anderson (Hospital and Tumor Institute) in 1983...
In this chapter, Dr. Brock sketches the development of his scientific and research interests during ...
Dr. Mills first tells how he was recruited to MD Anderson by Robert Bast, MD, VP of Translational Re...
Dr. Balch begins this chapter by commenting that he hired Dr. Grimm and Dr. Roth because they were r...
Dr. Roth begins this chapter with a few comments about his decision to come to MD Anderson from the ...
Dr. Cohen first tells the story of applying for a position at MD Anderson, noting that he wanted to ...
Dr. Tomasovic begins this segment with comments on MD Anderson’s perceived weaknesses in basic resea...
In this chapter, Dr. Jones explains that his mother\u27s breast cancer diagnosis motivated him to le...
Interest in Cancer: Dr. Knudson continues outlining his path towards discovering the two-hit model. ...
Dr. Gehan recollects Dr. R. Lee Clark’s approach to funding, recruitment, and management and the att...
Dr. Alexanian explains how he came to MD Anderson in 1964, then then talks about the evolution of hi...
Dr. Arlinghaus explains his reasons for focusing on leukemia research and the process of coming to M...
In this chapter, Dr. Jones talks about the graduate research that brought him to MD Anderson. He sk...
Dr. Jones talks his role in the Department of Gynecologic Oncology: to bring reproductive endocrinol...
To begin this segment, Dr. Rodriguez sketches her research while a Fellow at the University of Arizo...
In this segment, Dr. Kripke covers her arrival at MD Anderson (Hospital and Tumor Institute) in 1983...
In this chapter, Dr. Brock sketches the development of his scientific and research interests during ...
Dr. Mills first tells how he was recruited to MD Anderson by Robert Bast, MD, VP of Translational Re...
Dr. Balch begins this chapter by commenting that he hired Dr. Grimm and Dr. Roth because they were r...
Dr. Roth begins this chapter with a few comments about his decision to come to MD Anderson from the ...
Dr. Cohen first tells the story of applying for a position at MD Anderson, noting that he wanted to ...
Dr. Tomasovic begins this segment with comments on MD Anderson’s perceived weaknesses in basic resea...
In this chapter, Dr. Jones explains that his mother\u27s breast cancer diagnosis motivated him to le...
Interest in Cancer: Dr. Knudson continues outlining his path towards discovering the two-hit model. ...
Dr. Gehan recollects Dr. R. Lee Clark’s approach to funding, recruitment, and management and the att...
Dr. Alexanian explains how he came to MD Anderson in 1964, then then talks about the evolution of hi...
Dr. Arlinghaus explains his reasons for focusing on leukemia research and the process of coming to M...